Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sigyn Therapeutics, Inc. (SIGY : OTC)

• Company Description    Sigyn Therapeutics Inc. is a medical technology company. It is focused on the treatment of life-threatening inflammatory conditions. Sigyn Therapeutics Inc., formerly knonw as Reign Resources Corporation, is headquartered in San Diego, California USA. Number of Employees: 4

• Price / Volume Information    Yesterday's Closing Price: $2.75 Daily Weekly Monthly 20 Day Moving Average: 0 shares Shares Outstanding: 1.61 (millions) Market Capitalization: $4.41 (millions) Beta: -1.15 52 Week High: $5.75 52 Week Low: $2.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.00% -3.74% 12 Week -33.74% -44.26% Year To Date -12.70% -18.24%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2468 Historic Decatur Road Ste. 140 - San Diego,CA 92106 USA ph: 619-353-0800 fax: - charlene@sigyntherapeutics.com http://www.sigyntherapeutics.com

• General Corporate Information    Officers James Joyce - Chief Executive Officer and Director Richa Nand - Director Jim Dorst - Director - - - - - - Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 82674U205 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/18/25 Share - Related Items Shares Outstanding: 1.61 Most Recent Split Date: 1.00 (0.03:1) Beta: -1.15 Market Capitalization: $4.41 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/18/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 32.26% vs. Previous Quarter: 83.27% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -2,014.27 12/31/24 - -1,918.07 Current Ratio 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.00 Quick Ratio 06/30/25 - - 03/31/25 - 0.01 12/31/24 - 0.00 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -3.08 12/31/24 - -2.78 Inventory Turnover 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©